Roche's much-anticipated MS game-changer, Ocrevus, nabs its FDA green light

Roche's Ocrevus is the first med ever approved to treat primary progressive multiple sclerosis.

The new med Roche has been anticipating—and the multiple sclerosis market shake-up drugmakers have been dreading—is here.

On Tuesday, regulators approved the Swiss drugmaker’s Ocrevus to treat two forms of the disease—relapsing remitting MS and the harder-to-treat primary progressive form—in adult patients. The thumbs-up follows a three-month delay, when the agency asked Roche for additional data on the Ocrevus manufacturing process.

Now, the wait is over for Roche, which stands to win big with the blockbuster wannabe. It's pricing the med at $65,000 per year, marking a 25% discount to Merck KGaA rival Rebif, a drug it topped in clinical trials, and a 20% discount, on average, to other MS therapies, Mizuho analyst Salim Syed wrote in a note to clients.

On-Demand Webinar

De-Risking the Solid Form Landscape of an API

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. Attend to hear about two case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.

All told, EvaluatePharma has pegged Ocrevus as the No. 1 drug approval of 2017, at least in terms of 2022 sales; it’s predicting the newcomer will rack up $4.1 billion that year.

RELATED: The top 10 drug launches of 2017Ocrevus

One reason? Ocrevus is the first product ever to win approval for hard-to-treat primary progressive MS, which affects one in 10 MS sufferers, Roche says. And that’ll help the company "argue convincingly for a high price outside the U.S., resist payers in the U.S., and own the segment, without the competition that fragments" the $19 billion global market for relapsing disease, also known as RRMS, Bernstein analyst Tim Anderson has said.

That’s not to say Roche isn’t planning to make a splash in RRMS. It is—and in more ways than one. For starters, Ocrevus has already shown it can top industry heavyweight Rebif from Merck KGaA at quashing disease activity in that realm. It’s also an every-six-months infusion, meaning it’ll have a convenience edge over other infused meds such as Biogen’s Tysabri.

RELATED: Roche poised for MS coup with success in hard-to-treat progressive form

All things considered, Ocrevus’ arrival will "increase intermediate term formulary pressure" onto the already payer-squeezed RRMS space, Bernstein analyst Ronny Gal and other industry watchers have predicted.

For Roche, though, things are looking up, and approval is coming at an opportune time. Some of Roche’s key cancer giants—which have powered the Basel-based behemoth’s top line for years—are aging, with biosimilars makers lining up to attack.

Editor's note: This story has been updated with pricing information.

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.